Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of First-Time acute myocardial infarction

https://doi.org/10.1016/j.amjcard.2003.09.037Get rights and content

Abstract

We explored the association between diagnosed rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and the risk of developing a first-time acute myocardial infarction (AMI) by conducting a population-based, case-control analysis using data from the United Kingdom-based General Practice Research Database (GPRD). Among 8,688 patients with AMI and 33,329 matched controls, the adjusted odds ratio (ORs) of AMI for subjects with RA was 1.47 (95% confidence interval [CI] 1.23 to 1.76), and in subjects with both RA and diagnosed hyperlipidemia, the OR was 7.12 (95% CI 4.16 to 12.18). The risk associated with SLE was 2.67 (95% CI 1.34 to 5.34). These results underline that RA and SLE increase the risk of AMI.

References (15)

  • H. Jick

    A database worth saving

    Lancet

    (1997)
  • C.R. Meier et al.

    Acute respiratory tract infections and risk of first-time acute myocardial infarction

    Lancet

    (1998)
  • R. Ross

    Atherosclerosis—an inflammatory disease

    N Engl J Med

    (1999)
  • D.H. Solomon et al.

    Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

    Circulation

    (2003)
  • S. Wallberg-Jonsson et al.

    Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden

    J Rheumatol

    (1997)
  • I.D. del Rincon et al.

    High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors

    Arthritis Rheum

    (2001)
  • S. Manzi et al.

    Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosuscomparison with the Framingham Study

    Am J Epidemiol

    (1997)
There are more references available in the full text version of this article.

Cited by (0)

The Boston Collaborative Drug Surveillance Program was partly supported by grants from Hoffmann-La Roche, Basel, Switzerland. This study was not directly funded. Dr. Meier was supported by a grant from the Swiss National Science Foundation (grant No 32-67808.02), Basel, Switzerland. Dr. Matter was supported by the EU grant G5RD-CT-2001-00532, Brussels, Belgium; and by grant 02.0057 from the Bundesamt für Bildung und Wissenschaft, Bern, Switzerland.

View full text